Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
sanofi-aventis' Acomplia receives marketing authorization in Mexico
December 11th, 2006
Sanofi-aventis announced that Acomplia (rimonabant), the first medicine of a new class that targets multiple cardiometabolic risk factors, received marketing authorization from Mexican Health Authorities. The Ministry of Health, through the Federal Commission for Sanitary Risks Prevention (COFEPRIS), has granted the registration for Acomplia (rimonabant) in the following therapeutic indications: 1) as adjuvant to diet and exercise and/or any therapeutic scheme in obese (BMI > 30 kg/m2) or in overweight (BMI > 27 kg/m2) patients with associated risk factors such as type 2 diabetes or dyslipidemia; and 2) as adjuvant treatment...
Source: Obesity & Diabetes Week (2006-12-11)
|
